Approved for use through 10/31/2002. OMB 0651-0031

Under the Par	erwork	Reduction Act of 1995, no persons are required to response		unless it contains a valid OMB con		,015
Substitute for form 1449B/PTO			Complete if Known			
			Application Number	09/230,955		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	February 04, 1999	₩ G		
		First Named Inventor	Mason et al.	世 1		
		Group Art Unit	1642	<u> </u>		
(use as many sheets as necessary)		Examiner Name	Brumback, B.	62	$\Gamma$	
Sheet	1	OIPE of 1	Attorney Docket Number	A-67653/RFT/AMS	20/2	T
80						
Ryaminer Compared the latter of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the						
Examiner Initials*	97	iter book, magazine, journal, serial,	symposium, catalog, etc.), date, p c, city and/or country where publish	age(s), volume-issue number(s),		T²
iAC Yoka	Epenetos et al, "Targeting of iodine-123-labelled tumour-associated monoclonal antibodies to ovarian, bistantial gastrointestinal tumours," The Lancet, November 06, 1982, 999-1004.					
KAC	2	Epenetos, A.A., "Antibody guided lympha 51: 805-808 (1985).	angiography in the staging	of cervical cancer," Br. J.	of Cancer,	
KAC	3 .	Jha et al., "Monoclonal antibodies for the Journla of Obstetrics and Gynaecology, 91	l: 483-488 (1984).	TER 160	ECEN 語 1 2 2	
KAC	4	Porta et al., "Diagnosis of cervical carcinoma using the monoclonal antibodies technique Patorogia Clinica Ostetrica e Ginecologia, 14: 348-355 (1986). (Translation)				
		·				
						コ
Examiner 1 March 1. Gandla Date 19/2/03						
Examiner Signature	1 4	Heada Yaundak	Date Considered	5-27-02		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>&</sup>lt;sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English Language Translation is attached.